Cargando…
Treatment of biofilms in bacterial vaginosis by an amphoteric tenside pessary-clinical study and microbiota analysis
BACKGROUND: Bacterial vaginosis (BV) is the most common vaginal syndrome among women in their reproductive years. It is associated with an increased risk of acquiring sexually transmitted infections and complications like preterm labor. BV is characterized by a high recurrence rate for which biofilm...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5598074/ https://www.ncbi.nlm.nih.gov/pubmed/28903767 http://dx.doi.org/10.1186/s40168-017-0326-y |
_version_ | 1783263828728872960 |
---|---|
author | Gottschick, Cornelia Deng, Zhi-Luo Vital, Marius Masur, Clarissa Abels, Christoph Pieper, Dietmar H. Rohde, Manfred Mendling, Werner Wagner-Döbler, Irene |
author_facet | Gottschick, Cornelia Deng, Zhi-Luo Vital, Marius Masur, Clarissa Abels, Christoph Pieper, Dietmar H. Rohde, Manfred Mendling, Werner Wagner-Döbler, Irene |
author_sort | Gottschick, Cornelia |
collection | PubMed |
description | BACKGROUND: Bacterial vaginosis (BV) is the most common vaginal syndrome among women in their reproductive years. It is associated with an increased risk of acquiring sexually transmitted infections and complications like preterm labor. BV is characterized by a high recurrence rate for which biofilms frequently found on vaginal epithelial cells may be a reason. RESULTS: Here, we report a controlled randomized clinical trial that tested the safety and effectiveness of a newly developed pessary containing an amphoteric tenside (WO3191) to disrupt biofilms after metronidazole treatment of BV. Pessaries containing lactic acid were provided to the control group, and microbial community composition was determined via Illumina sequencing of the V1-V2 region of the 16S rRNA gene. The most common community state type (CST) in healthy women was characterized by Lactobacillus crispatus. In BV, diversity was high with communities dominated by either Lactobacillus iners, Prevotella bivia, Sneathia amnii, or Prevotella amnii. Women with BV and proven biofilms had an increased abundance of Sneathia sanguinegens and a decreased abundance of Gardnerella vaginalis. Following metronidazole treatment, clinical symptoms cleared, Nugent score shifted to Lactobacillus dominance, biofilms disappeared, and diversity (Shannon index) was reduced in most women. Most of the patients responding to therapy exhibited a L. iners CST. Treatment with WO 3191 reduced biofilms but did not prevent recurrence. Women with high diversity after antibiotic treatment were more likely to develop recurrence. CONCLUSIONS: Stabilizing the low diversity healthy flora by promoting growth of health-associated Lactobacillus sp. such as L. crispatus may be beneficial for long-term female health. TRIAL REGISTRATION: ClinicalTrials.gov NCT02687789 ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40168-017-0326-y) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5598074 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-55980742017-09-18 Treatment of biofilms in bacterial vaginosis by an amphoteric tenside pessary-clinical study and microbiota analysis Gottschick, Cornelia Deng, Zhi-Luo Vital, Marius Masur, Clarissa Abels, Christoph Pieper, Dietmar H. Rohde, Manfred Mendling, Werner Wagner-Döbler, Irene Microbiome Research BACKGROUND: Bacterial vaginosis (BV) is the most common vaginal syndrome among women in their reproductive years. It is associated with an increased risk of acquiring sexually transmitted infections and complications like preterm labor. BV is characterized by a high recurrence rate for which biofilms frequently found on vaginal epithelial cells may be a reason. RESULTS: Here, we report a controlled randomized clinical trial that tested the safety and effectiveness of a newly developed pessary containing an amphoteric tenside (WO3191) to disrupt biofilms after metronidazole treatment of BV. Pessaries containing lactic acid were provided to the control group, and microbial community composition was determined via Illumina sequencing of the V1-V2 region of the 16S rRNA gene. The most common community state type (CST) in healthy women was characterized by Lactobacillus crispatus. In BV, diversity was high with communities dominated by either Lactobacillus iners, Prevotella bivia, Sneathia amnii, or Prevotella amnii. Women with BV and proven biofilms had an increased abundance of Sneathia sanguinegens and a decreased abundance of Gardnerella vaginalis. Following metronidazole treatment, clinical symptoms cleared, Nugent score shifted to Lactobacillus dominance, biofilms disappeared, and diversity (Shannon index) was reduced in most women. Most of the patients responding to therapy exhibited a L. iners CST. Treatment with WO 3191 reduced biofilms but did not prevent recurrence. Women with high diversity after antibiotic treatment were more likely to develop recurrence. CONCLUSIONS: Stabilizing the low diversity healthy flora by promoting growth of health-associated Lactobacillus sp. such as L. crispatus may be beneficial for long-term female health. TRIAL REGISTRATION: ClinicalTrials.gov NCT02687789 ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40168-017-0326-y) contains supplementary material, which is available to authorized users. BioMed Central 2017-09-13 /pmc/articles/PMC5598074/ /pubmed/28903767 http://dx.doi.org/10.1186/s40168-017-0326-y Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Gottschick, Cornelia Deng, Zhi-Luo Vital, Marius Masur, Clarissa Abels, Christoph Pieper, Dietmar H. Rohde, Manfred Mendling, Werner Wagner-Döbler, Irene Treatment of biofilms in bacterial vaginosis by an amphoteric tenside pessary-clinical study and microbiota analysis |
title | Treatment of biofilms in bacterial vaginosis by an amphoteric tenside pessary-clinical study and microbiota analysis |
title_full | Treatment of biofilms in bacterial vaginosis by an amphoteric tenside pessary-clinical study and microbiota analysis |
title_fullStr | Treatment of biofilms in bacterial vaginosis by an amphoteric tenside pessary-clinical study and microbiota analysis |
title_full_unstemmed | Treatment of biofilms in bacterial vaginosis by an amphoteric tenside pessary-clinical study and microbiota analysis |
title_short | Treatment of biofilms in bacterial vaginosis by an amphoteric tenside pessary-clinical study and microbiota analysis |
title_sort | treatment of biofilms in bacterial vaginosis by an amphoteric tenside pessary-clinical study and microbiota analysis |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5598074/ https://www.ncbi.nlm.nih.gov/pubmed/28903767 http://dx.doi.org/10.1186/s40168-017-0326-y |
work_keys_str_mv | AT gottschickcornelia treatmentofbiofilmsinbacterialvaginosisbyanamphoterictensidepessaryclinicalstudyandmicrobiotaanalysis AT dengzhiluo treatmentofbiofilmsinbacterialvaginosisbyanamphoterictensidepessaryclinicalstudyandmicrobiotaanalysis AT vitalmarius treatmentofbiofilmsinbacterialvaginosisbyanamphoterictensidepessaryclinicalstudyandmicrobiotaanalysis AT masurclarissa treatmentofbiofilmsinbacterialvaginosisbyanamphoterictensidepessaryclinicalstudyandmicrobiotaanalysis AT abelschristoph treatmentofbiofilmsinbacterialvaginosisbyanamphoterictensidepessaryclinicalstudyandmicrobiotaanalysis AT pieperdietmarh treatmentofbiofilmsinbacterialvaginosisbyanamphoterictensidepessaryclinicalstudyandmicrobiotaanalysis AT rohdemanfred treatmentofbiofilmsinbacterialvaginosisbyanamphoterictensidepessaryclinicalstudyandmicrobiotaanalysis AT mendlingwerner treatmentofbiofilmsinbacterialvaginosisbyanamphoterictensidepessaryclinicalstudyandmicrobiotaanalysis AT wagnerdoblerirene treatmentofbiofilmsinbacterialvaginosisbyanamphoterictensidepessaryclinicalstudyandmicrobiotaanalysis |